EZH2 and cancer: In light of these developments, the thorough elucidation of the molecular subtypes and the context-defining cues determining canonical or non-canonical oncogenic EZH2 activity in PDAC and other malignancies might pave the way for the stratified and efficient implementation of EZH2-targeting in cancer treatment.